High-Dose Radiation Improves Lung Cancer Survival, U-M Study Finds
Posted on: Wednesday, 8 April 2009, 08:42 CDT
Concurrent chemotherapy, radiation also linked to better survival
Standard treatment for this stage of lung cancer -- when the tumor is likely too large to be removed through surgery -- involves a combination of radiation therapy with chemotherapy. But, this new study finds, giving chemotherapy at the same time as the radiation enhances the effect of both. Further, increasing the dose of radiation over the course of treatment also increased survival.
"When patients are diagnosed with stage III lung cancer, surgery is often not an option, and survival rates are typically quite low. Finding new ways to improve survival, even in small increments, is crucial," says senior study author
The study, published in the
The researchers compared survival among patients treated with radiation alone, with radiation followed by chemotherapy, and with radiation and chemotherapy given at the same time. Thirty-one of the patients were also enrolled in a study in which the radiation dose was increased throughout the course of the treatment.
Patients treated with radiation alone had the worst overall survival rates, living only an average 7.4 months after diagnosis. Adding chemotherapy increased survival to 14.9 months when it was administered after completing radiation and 15.8 months when administered at the same time as radiation. After five years, 19.4 percent of the patients receiving concurrent chemotherapy were still alive, compared to only 7.5 percent of patients receiving sequential chemotherapy.
"Our study shows chemotherapy helps, and high dose radiation helps. But it's challenging to administer these treatments at the same time because of the potential toxicity associated with the high dose radiation," Kong says.
U-M researchers are currently looking at using PET imaging during the course of lung cancer treatment to personalize high dose radiation therapy in many individual patients. As the tumor becomes smaller during treatment, increasing the radiation dose will become more tolerable because it is targeting a smaller area. The U-M researchers believe this strategy could lead to improved treatment outcomes in many patients. Kong currently leads a clinical trial that is following patients through their treatment to look at the impact on survival of increasing radiation dose.
Lung cancer statistics: 215,000 Americans will be diagnosed with lung cancer this year and 161,800 will die from the disease, according to the American Cancer Society
Additional authors:
Funding: Pardee Foundation, American Society of Clinical Oncology Career Development Award
Reference: International Journal of Radiation Oncology*Biology*Physics, Vol. 73, No. 5, pp. 1383-1390
Resources:
U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, www.mcancer.org
SOURCE
Source: PR Newswire
Related Articles
- 2/3 Of Prostate Cancer Patients Do Not Need Treatment
- Online Tool for Prostate Cancer Patients Helps Men Customize Treatment During Anxious Time
- New website empowers colorectal cancer patients when discussing critical treatment decisions - DiagnoCure launches www.mypersonalcancerdiagnosis.com
- Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
- Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity
- New Web Site Helps Cancer Patients Stay Strong Through Treatment
- Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
- Cyberonics Announces Patient Enrollment in New TRD Dosing Study
- Teen Cancer Patient to Get Alt. Treatment
- XYOTAX(TM) Significantly Prolongs Survival in Poor Performance Status (PS2) Non-Small Cell Lung Cancer Patients Compared to Standard Treatment With Vinorelbine
User Comments (0)

RSS Feeds